Janssen Ceases Development of RSV Vaccine for Adults
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Tag: clinical trials
All
Latest
All
Latest
COPD: Nebulized Ensifentrine Improved Lung Function, Reduced Exacerbations
A phase 3 clinical trial revealed that treatment with nebulized ensifentrine led to significant improvements in lung function, symptoms and quality of life measures in COPD patients.
All
Latest
Tezepelumab Improved Severe Asthma in Half of Patients
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
Itepekimab Monotherapy Improved Asthma Lung Function
Itepekimab monotherapy is associated with a lower rate of asthma exacerbations and improved lung function, new research found.
Read More
Regen-Cov Reduced COVID Risk for up to Eight Months
A single dose of Regeneron Pharma’s antibody cocktail casirivimab and imdevimab (trade name Regen-Cov) reduced the risk of COVID-19 by 81.6% for up to eight months, according to a Phase 3 trial.
Read More
The Evaluation of Cytisinicline in Cessation of E-cigarette Use, Nicotine Addiction
The National Institutes of Health has awarded Achieve Life Sciences a grant to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use.
Read More
Clinical Trial of RSV Vaccine Underway
MV-012-968 is an intranasal live attenuated RSV vaccine candidate being developed as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults.
Read More
NIH to Study Antibody Responses in Vaccinated Pregnant Women and Their Infants
The NIH has begun evaluating the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum women and their infants.
Read More
How Effective is Azithromycin for Treating Cough in Idiopathic Pulmonary Fibrosis?
Low dose azithromycin for cough did not show significant improvements compared with placebo in patients with idiopathic pulmonary fibrosis.
Read More
NIH Begins Research into Mixed COVID-19 Booster Vaccines
An NIH Phase 1/2 clinical trial will study fully-vaccinated adult volunteers who will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens.
Read More
Long-term Data Shows Safety, Effectiveness of Fasenra for Severe Eosinophilic Asthma
A five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
Read More
Clinical Trial Begins for 2nd-Gen COVID-19 Vaccine
A Phase I/II clinical trial in the Netherlands will test AKS-452, a COVID-19 vaccine candidate that is shelf-stable for at least 4 months without refrigeration.
Read More
NIH to Trial Repurposed Drugs for COVID-19
A Phase 3 clinical trial will explore a pool of up to seven drugs approved by FDA for other conditions – an approach called drug repurposing – and test their safety and effectiveness in treating mild to moderate COVID-19.
Read More
Experimental Antiviral MK-4482 Effective for SARS-CoV-2
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.
Read More
Regeneron Monoclonal Antibodies Reduced COVID-19 Transmission Risk by 81%
Regen-CoV — a monoclonal antibody cocktail from Regeneron — reduced the risk of symptomatic SARS-CoV-2 infections by 81% in a Phase 3 clinical trial.
Read More